Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
5(45%)
Results Posted
0%(0 trials)
Terminated
2(18%)

Phase Distribution

Ph phase_3
3
27%
Ph phase_1
1
9%
Ph phase_4
3
27%
Ph phase_2
3
27%

Phase Distribution

1

Early Stage

3

Mid Stage

6

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
3(30.0%)
Phase 3Large-scale testing
3(30.0%)
Phase 4Post-market surveillance
3(30.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

5

trials recruiting

Total Trials

11

all time

Status Distribution
Active(5)
Completed(2)
Terminated(2)
Other(2)

Detailed Status

Recruiting3
Completed2
unknown2
Active, not recruiting2
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
11
Active
5
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (10.0%)
Phase 23 (30.0%)
Phase 33 (30.0%)
Phase 43 (30.0%)

Trials by Status

completed218%
unknown218%
recruiting327%
active_not_recruiting218%
terminated218%

Recent Activity

Clinical Trials (11)

Drug Details

Intervention Type
DRUG
Total Trials
11